Chronic enteropathy associated with solute carrier organic anion transporter family member 2A1 gene (usually shortened to “CEAS” or “chronic enteropathy associated with SLCO2A1”) is a rare inherited bowel disease. In this condition, both copies of the SLCO2A1 gene carry harmful changes (mutations). This gene normally makes a “prostaglandin transporter” protein that sits in the cell membrane and helps move prostaglandins (signaling molecules) into cells so they can be broken down. When the transporter does not work properly, prostaglandin E2 (PGE2) builds up around the gut wall and other tissues, which increases inflammation and slowly damages the small intestine. Patients develop multiple, shallow ulcers in the small intestine, long-lasting blood and protein loss, anemia, swelling, and low body weight. CEAS can start in childhood or young adulthood and is often mistaken for Crohn’s disease.
Because CEAS is genetic, it usually follows an autosomal-recessive pattern: the child inherits one mutated SLCO2A1 gene from each parent, who are typically healthy carriers. The disease most often affects the small intestine, especially the ileum, and causes chronic iron deficiency anemia, low albumin, and sometimes growth delay in children. Blood tests may show normal inflammatory markers even while the bowel is inflamed, which makes diagnosis harder. Endoscopy or capsule endoscopy reveals multiple non-specific ulcers, and genetic testing confirms SLCO2A1 mutations. There is no specific “cure” yet; current care mainly aims to correct anemia and protein loss, maintain nutrition, and prevent complications such as strictures and bowel obstruction.
Chronic enteropathy associated with solute carrier organic anion transporter family member 2A1 gene is usually called chronic enteropathy associated with SLCO2A1 gene or CEAS. It is a rare, life-long gut disease. In this disease, many small, shallow ulcers form in the small intestine and stay for a long time. These ulcers cause slow blood loss and loss of protein into the gut.
The SLCO2A1 gene gives the body instructions to make a transport protein called a prostaglandin transporter. Prostaglandins are small, hormone-like chemicals that help protect the lining of the gut and control inflammation. When this gene does not work properly, prostaglandins cannot move correctly inside cells. This can damage the small intestine lining and lead to long-lasting ulcers.
CEAS is an autosomal recessive disease. This means a child gets one faulty copy of the SLCO2A1 gene from each parent. Parents are usually healthy carriers. The condition often starts in childhood or young adulthood and may be mistaken for Crohn’s disease or other inflammatory bowel diseases, because the symptoms can look very similar.
Over time, people with CEAS may develop anemia (low red blood cells) and low blood protein. Some patients also show bone and skin changes, like thickened skin on the scalp or fingers and joint pain, because the same gene is also linked to a bone-and-skin condition called primary hypertrophic osteoarthropathy.
Other names
Doctors and researchers use several other names for this same disease:
-
Chronic enteropathy associated with SLCO2A1 gene (CEAS) – the current preferred name in many articles.
-
Chronic nonspecific multiple ulcers of the small intestine (CNSU) – this was the old name used before the gene cause was known. It describes many ulcers in the small intestine with no clear cause.
-
Chronic non-specific multiple ulcer of the small intestine – a very similar phrase used in early Japanese reports in the 1960s and 1970s.
-
Monogenic chronic enteropathy due to SLCO2A1 mutation – this name stresses that one single gene error (monogenic) causes a long-term bowel disease.
-
SLCO2A1-related small bowel ulcer disease – a descriptive research term used to highlight that the ulcers are in the small bowel and linked to SLCO2A1 variants.
Types
There is only one main genetic disease, but doctors often group cases into “types” based on age, symptoms, or extra-intestinal features. These are practical groups, not strict official subtypes.
-
Childhood-onset CEAS – symptoms start in childhood, often with anemia, poor growth, and early small bowel ulcers. This form may be counted as a type of very-early-onset inflammatory bowel disease.
-
Adolescent or adult-onset CEAS – symptoms appear in teenage years or adulthood. Patients may have many years of iron-deficiency anemia before the ulcers are found.
-
CEAS with mainly small bowel disease – most ulcers are in the jejunum and ileum (middle and last part of small intestine). This is the classic picture.
-
CEAS with Crohn-like disease – in some people, the ulcers and inflammation look very similar to Crohn’s disease on imaging and endoscopy, so the condition can be misdiagnosed.
-
CEAS with bone and skin changes (overlap with hypertrophic osteoarthropathy) – some patients also have thickened skin, clubbed fingers, and periosteal new bone formation because SLCO2A1 mutations can also cause primary hypertrophic osteoarthropathy type 2.
-
Gene-variant-based groupings – researchers sometimes group patients by which exact SLCO2A1 variants they carry, for example “loss-of-function frameshift variant” or “compound heterozygous missense plus deletion,” because different variants may have slightly different clinical features.
Causes
In strict science, the main cause of CEAS is mutation of the SLCO2A1 gene. Many of the “causes” below are actually risk factors, genetic patterns, or disease mechanisms that lead to or worsen this same process.
-
Pathogenic SLCO2A1 gene variants
Harmful changes in the DNA sequence of the SLCO2A1 gene cause the transporter protein to be missing or not work well. This is the core cause of CEAS in all confirmed patients. -
Autosomal recessive inheritance
A child must receive one faulty SLCO2A1 copy from each parent. When both copies are changed, the prostaglandin transporter fails, and chronic enteropathy can develop. -
Loss of prostaglandin transporter function
The SLCO2A1 protein normally brings prostaglandins like PGE₂ into cells where they can be broken down. If this transport fails, prostaglandin handling becomes abnormal, and the small bowel mucosa is harmed. -
Prostaglandin imbalance in the intestine
When prostaglandins cannot move correctly into intestinal cells, local levels and signaling become abnormal. This can reduce mucosal protection and change inflammation, leading to ulcers and bleeding. -
Chronic, low-grade intestinal inflammation
Abnormal prostaglandin handling and a weakened mucosal barrier can keep the immune system “switched on” in the gut. Over time, this chronic inflammation damages the small intestine wall. -
Family history of CEAS or related SLCO2A1 disease
Because it is inherited, families with known CEAS or SLCO2A1-related bone/skin disease have a higher chance of having affected children if both parents are carriers. -
Consanguinity (parents related by blood)
When parents are related (for example cousins), they are more likely to carry the same rare gene variant. This increases the chance that a child gets two faulty SLCO2A1 copies. -
Asian ancestry (especially East Asian)
Many of the first and largest patient groups were reported in Japan, Korea, and China. This suggests some SLCO2A1 variants may be more common in these populations, although cases are now seen worldwide. -
Very-early-onset inflammatory bowel disease background
CEAS is one example of monogenic very-early-onset IBD. Children who present with IBD-like symptoms at a very young age may have an underlying gene defect such as SLCO2A1 mutation. -
Epigenetic changes in SLCO2A1 expression
Some research in pediatric IBD shows reduced SLCO2A1 expression due to DNA methylation. While this is not classic CEAS, it suggests that changes in how the gene is turned on or off may also affect gut health. -
Coexisting primary hypertrophic osteoarthropathy (PHO)
The same SLCO2A1 mutations can cause PHO with clubbing and bone changes. These patients may also develop CEAS because the gene problem affects both bone/skin and gut. -
Modifier genes
Other genes that affect inflammation, mucosal repair, or prostaglandin pathways may change how severe CEAS becomes. This idea comes from differences seen among patients with similar SLCO2A1 variants. -
Environmental triggers (unknown)
Many patients report symptom flares without a clear trigger. It is suspected that infections, diet changes, or stress might worsen the disease, but strong proof is limited so far. -
Impaired wound healing in intestinal mucosa
The prostaglandin transporter is important for tissue repair. When its function is disturbed, ulcers may heal slowly, so small injuries in the small intestine can become chronic, non-healing ulcers. -
Altered macrophage and inflammasome activity
Experimental models show that Slco2a1 deficiency can raise PGE₂ in tissues and activate the NLRP3 inflammasome in immune cells, which may drive extra gut inflammation. -
Gut microbiota imbalance (possible)
Long-lasting ulcers, repeated antibiotic use, and chronic inflammation can disturb the normal gut bacteria. This imbalance may not cause CEAS by itself but can worsen symptoms. -
Delayed or missed diagnosis
When CEAS is mistaken for Crohn’s disease or “idiopathic” small bowel ulcers, targeted care is delayed. Ongoing damage then continues and may make the disease seem more severe. -
Repeated use of non-steroidal anti-inflammatory drugs (NSAIDs) in some patients
NSAIDs can cause small bowel ulcers in general. CEAS was first described as ulcers “not related to NSAIDs,” but if a person with CEAS uses NSAIDs, these drugs might deepen or worsen ulceration. -
Severe iron-deficiency anemia and malnutrition
Anemia and low protein are results of CEAS, but they can also impair healing and immune function. This may keep ulcers active and maintain the disease cycle. -
Surgical resection of bowel segments (secondary worsening)
Some patients need surgery to remove diseased segments. Later, new ulcers can appear at other sites. This does not cause CEAS but shows that surgery alone cannot remove the underlying genetic problem, and disease can continue.
Symptoms
-
Chronic abdominal pain
Many patients have long-lasting belly pain, often around the middle or lower abdomen. Pain may be dull or crampy and often links to active ulcers or mild bowel narrowing. -
Iron-deficiency anemia
Slow bleeding from small bowel ulcers leads to low iron and low hemoglobin. People may feel very tired, weak, or short of breath, and they may look pale. -
Low blood protein and leg swelling
Protein can leak from the damaged intestine, lowering blood albumin. Low albumin can cause swelling in the legs, feet, or abdomen (edema or ascites), and people may gain “water weight.” -
Unexplained weight loss
Poor nutrient absorption, loss of protein, poor appetite, and fear of pain after eating can all cause weight loss over months or years. -
Poor growth in children
Children with CEAS may grow more slowly than expected, may be shorter than peers, or may enter puberty late because of long-term under-nutrition and chronic disease. -
Diarrhea or frequent loose stools
Some patients have loose stools, sometimes with mucus or small amounts of blood. Others may have fairly normal stools but still lose blood that is not visible (occult blood). -
Dark or bloody stools (overt bleeding)
When bleeding is more intense, stool may look dark and tarry or clearly bloody. This is a sign that ulcers are actively bleeding and needs quick medical care. -
Nausea and vomiting
If ulcers cause narrowing or if inflammation is strong, people may feel sick after eating and sometimes vomit. This can worsen weight loss and dehydration. -
Loss of appetite
Chronic pain, nausea, and emotional stress can reduce appetite. This makes it even harder to keep a healthy weight and maintain normal blood protein and vitamins. -
Fatigue and low exercise tolerance
Anemia, low protein, and chronic inflammation cause severe tiredness. People may not be able to do usual school, work, or sports activities. -
Headache, dizziness, or faintness
Very low hemoglobin reduces oxygen to the brain. This can cause headaches, light-headed feelings, or even fainting, especially when standing up quickly. -
Clubbing of fingers and toes
In some patients with associated hypertrophic osteoarthropathy, the tips of the fingers and toes become round and bulb-shaped. This change develops slowly over years. -
Bone and joint pain
People who have both CEAS and SLCO2A1-related bone disease can have painful, swollen joints and thickened bones under the skin, especially in the legs and arms. -
Intermittent fever or feeling unwell
During flares of intestinal inflammation, patients may have mild fever, body aches, or just feel generally sick and tired. -
Emotional stress, anxiety, or low mood
Living with a rare, chronic disease with repeated hospital visits and tests can cause worry and sadness. These symptoms are real and need support and care just like physical signs.
Diagnostic tests
Below are 20 important tests. They are grouped by type, but numbers continue from start to end. Many tests are used to support the diagnosis and to rule out other diseases like Crohn’s disease or NSAID-induced ulcers.
Physical exam tests
-
Full medical history and general physical examination (Physical exam)
The doctor asks about symptoms, family history, growth, diet, and medicines. They examine the whole body for pale skin, swelling, weight loss, and signs of chronic disease. This first step guides which detailed tests are needed. -
Abdominal examination (Physical exam)
The doctor gently presses different parts of the abdomen to look for pain, tenderness, lumps, or fluid. In CEAS, the abdomen may be mildly tender but often without a big mass. This exam helps decide where ulcers or strictures might be. -
Skin, hair, and nail examination (Physical exam)
The doctor checks for clubbing of fingers, thickened skin on scalp, face, or hands, and oily skin or excessive sweating, which may suggest SLCO2A1-related bone and skin disease along with enteropathy. -
Growth and nutrition assessment (Physical/manual)
Height, weight, and body mass index are measured and plotted on growth charts. In children with CEAS, growth may be behind age norms. This helps show chronic under-nutrition from long-term gut disease.
Manual tests
-
Abdominal pain mapping (Manual exam)
The doctor presses gently in different areas and asks the patient to point to where it hurts most. This simple test helps find patterns of pain and may suggest small bowel involvement rather than stomach or colon alone. -
Stool diary and symptom log (Manual/clinical tool)
Patients record how often they pass stool, the look of the stool, and any blood, pain, or fever. This diary helps doctors understand how active the disease is over days or weeks. -
Food diary and elimination testing (Manual/clinical tool)
Writing down all foods and any symptoms can sometimes show if certain meals worsen pain or diarrhea. While CEAS is genetic, this tool can help manage symptoms and exclude strong food triggers. -
Joint movement and tenderness check (Manual exam)
The doctor gently moves the joints and presses over bones to look for pain or swelling. This helps detect associated hypertrophic osteoarthropathy or arthritis, which can appear with SLCO2A1 mutations.
Lab and pathological tests
-
Complete blood count (CBC) (Lab test)
CBC measures hemoglobin, red cells, white cells, and platelets. In CEAS, anemia is common, often with small red cells due to iron deficiency, and sometimes mild changes in other cell counts. -
Serum protein, albumin, and liver/kidney function tests (Lab test)
These blood tests show if protein is low (hypoproteinemia, hypoalbuminemia) and help rule out liver or kidney causes of edema. In CEAS, albumin is often low because protein is lost through the gut. -
Iron studies (serum iron, ferritin, TIBC) (Lab test)
Iron tests confirm iron-deficiency anemia and help separate it from other anemia types. Low ferritin and low serum iron with high total iron-binding capacity are typical when blood loss from ulcers has been long term. -
Inflammatory markers (CRP, ESR) (Lab test)
C-reactive protein and erythrocyte sedimentation rate can be slightly or moderately raised in active disease. Values may help monitor flare and response to treatment, but they are not specific for CEAS. -
Stool tests: occult blood, infection, and sometimes calprotectin (Lab test)
Stool occult blood detects hidden bleeding. Tests for bacteria, parasites, and viruses help rule out infection. Calprotectin may show intestinal inflammation but does not tell the exact cause. -
Genetic testing for SLCO2A1 variants (Lab/genetic test)
This is the key confirmatory test. A blood sample is used to read the SLCO2A1 gene. Finding disease-causing variants in both copies of the gene confirms CEAS and separates it from Crohn’s disease and other causes. -
Endoscopy with small bowel biopsy (Pathological test)
Using a special enteroscope, usually double-balloon enteroscopy, doctors can see the small intestine and take tissue samples from ulcers. Biopsies often show non-specific inflammation and shallow ulcers without typical Crohn’s features.
Electrodiagnostic tests
-
Electrocardiogram (ECG) (Electrodiagnostic test)
An ECG records the heart’s electrical activity. In CEAS, it is used mainly to check if severe anemia or low protein has affected the heart, especially before anesthesia or major procedures. It does not diagnose CEAS but supports safe care. -
Electromyography or nerve conduction studies (Electrodiagnostic test, selected cases)
These tests measure how muscles and nerves work. They are not routine for CEAS but may be used if a patient with long-term malnutrition or bone disease has unexplained limb weakness or nerve symptoms.
Imaging tests
-
Capsule endoscopy of the small intestine (Imaging/endoscopic test)
The patient swallows a tiny camera capsule that takes pictures throughout the small intestine. This test is very useful for finding multiple small ulcers that were missed by standard upper and lower endoscopy. -
CT enterography (Imaging test)
CT enterography uses contrast dye and special scanning to show the small bowel. It can reveal segmental wall thickening, narrowed segments, and areas where ulcers are clustered, which is typical in CEAS. -
MR enterography or small bowel MRI (Imaging test)
MRI with enterography technique can show similar findings without radiation. It helps assess the length and severity of diseased segments and can be repeated over time to monitor progression or response to therapy.
Non-pharmacological treatments (therapies and other measures)
There is no definitive non-drug therapy proven to switch off CEAS, but several supportive strategies can reduce symptoms and complications. These approaches should always be planned and monitored by a gastroenterologist or pediatric specialist, because CEAS is complex and rare.
-
Individualized enteral nutrition (liquid or semi-elemental diet)
A carefully planned liquid or semi-elemental diet provides calories, protein, vitamins, and minerals in a form that is easier for the damaged small intestine to absorb. Dietitians often use low-fat, low-fiber formulas to reduce mechanical irritation to ulcers and limit stool volume. The purpose is to improve weight, correct malnutrition, and give the bowel some rest from large, bulky meals. The main mechanism is reduction of physical stress on inflamed segments and improved nutrient delivery to the mucosa, which can help stabilize anemia and low albumin. -
Total parenteral nutrition (TPN) in severe disease
In advanced CEAS with very poor absorption or after major surgery, nutrients may need to be given directly into a vein as total parenteral nutrition. A central venous catheter delivers balanced solutions of amino acids, glucose, lipids, vitamins, and trace elements. The purpose is to maintain life, weight, and healing when the bowel is unable to absorb enough food. Mechanistically, TPN bypasses the gut completely, preventing further irritation of ulcers while still providing all essential nutrients, but it carries risks such as infection and liver problems, so it is reserved for selected patients. -
Iron-rich dietary pattern with low-residue modifications
Diet alone cannot correct severe anemia in CEAS, but an iron-rich diet (lean red meat where culturally acceptable, poultry, fish, eggs, iron-fortified foods, and plant sources eaten with vitamin C) can support medical iron therapy. Low-residue (low-fiber) adjustments reduce bulky plant fibers that may scrape ulcers and worsen pain. The purpose is to gently support iron stores and reduce stool volume. The mechanism is straightforward: provide easily absorbed iron while minimizing mechanical irritation and diarrhea from large amounts of insoluble fiber. -
High-protein, energy-dense oral supplements
Because protein loss through the gut is common, high-protein drinks, puddings, or powders are often added to the diet. These can be sipped between meals to avoid large volume in the intestine at one time. The purpose is to rebuild albumin levels and muscle mass, reduce edema, and support wound healing. Mechanistically, the extra protein and calories help the liver make more blood proteins and support tissue repair in the bowel and other organs. -
Avoidance of NSAIDs and other mucosal irritants
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen can damage the small-bowel mucosa even in healthy people, and this effect may be worse in CEAS. The purpose of avoidance is to reduce added ulceration on top of the genetic problem. The mechanism involves removing drugs that inhibit prostaglandin synthesis and directly injure the mucosa, thereby lowering the chance of new ulcers, bleeding, and strictures. Patients should always discuss safe pain-relief alternatives with their doctors. -
Careful fluid and salt management for edema and low albumin
Low albumin makes fluid leak into tissues, causing swelling of the legs or face and sometimes fluid in the abdomen. Doctors may recommend carefully balanced salt intake, elevation of swollen limbs, and in some cases compression stockings. The purpose is to reduce discomfort and risk of skin breakdown. The mechanism is based on basic fluid dynamics: improving albumin (through nutrition and albumin infusions) and controlling salt and fluid intake helps keep fluid inside blood vessels instead of in tissues. -
Vaccination and infection-prevention strategies
Because patients may receive immunosuppressive drugs or have central venous lines, vaccination against influenza, pneumococcus, COVID-19, and other recommended pathogens is very important. The purpose is to prevent severe infections that can be life-threatening in undernourished or immunosuppressed people. Mechanistically, vaccines prime the immune system to react faster and more effectively, reducing the chance that infections will trigger flares, hospitalizations, or surgery. -
Psychological support and counseling
Living with a chronic, poorly understood bowel disease is emotionally stressful, especially for children and adolescents who may face growth delay or repeated hospital stays. Counseling, support groups, and school-based support help patients and families cope with uncertainty, fatigue, and dietary restrictions. The purpose is to reduce anxiety, depression, and social isolation. Mechanistically, better mental health can improve treatment adherence, appetite, and overall resilience, which indirectly supports physical recovery. -
Genetic counseling for patients and families
Because CEAS is linked to inherited SLCO2A1 mutations, families benefit from meeting a genetic counselor to discuss recurrence risk, testing of siblings, and reproductive choices. The purpose is informed decision-making and early detection in at-risk relatives. Mechanistically, identifying affected or carrier relatives early allows close monitoring of anemia and growth, earlier imaging of the small intestine, and timely treatment before severe complications develop. -
Regular structured follow-up in a specialist center
Given the rarity of CEAS, follow-up in a center familiar with rare monogenic intestinal disorders is ideal. Routine monitoring of weight, growth (in children), blood counts, albumin, and imaging when needed allows early detection of strictures or new ulcers. The purpose is to prevent emergencies and plan surgery or nutritional support in a controlled way. The mechanism is proactive care: problems are seen early and handled before they become life-threatening.
Drug treatments
At present, there is no drug approved specifically to cure CEAS, and medications that work in Crohn’s disease (corticosteroids, 5-ASA, anti-TNF agents) are often ineffective or only partly helpful. Most medicines are used to treat complications such as anemia, protein loss, pain, or strictures. All drug choices and doses must be decided by a specialist; nothing here should be used for self-medication.
Below are examples of key drug categories often used; in practice, only a subset will be chosen for any one patient.
-
Intravenous ferric carboxymaltose for iron deficiency anemia
Ferric carboxymaltose (for example, Injectafer) is an intravenous (IV) iron preparation used when oral iron is not effective or not tolerated. In CEAS, chronic bleeding and poor absorption make IV iron very important. The purpose is to rapidly restore iron stores and hemoglobin, improving fatigue, breathlessness, and heart strain. Mechanistically, ferric carboxymaltose delivers a large amount of bioavailable iron directly into the bloodstream, bypassing the damaged gut. Typical dosing is based on body weight and anemia severity according to the FDA label, given as one or two infusions, with possible repeats if anemia returns. Main risks include allergic reactions, transient high blood pressure, and low phosphate levels. -
Oral iron (ferrous salts) when absorption is adequate
Some patients with milder disease can use oral iron tablets or syrups (such as ferrous sulfate or ferrous fumarate). The purpose is the same as IV iron: replenishing iron and supporting red-blood-cell production. Mechanistically, iron is absorbed in the upper small intestine and used by the bone marrow to produce hemoglobin. Dosing is individualized and often lower than traditional schedules to reduce stomach upset. Side effects include nausea, constipation or diarrhea, dark stools, and tooth staining with liquids. In CEAS, doctors often switch to IV iron if oral iron fails or worsens symptoms. -
Human albumin infusion for severe hypoalbuminemia
When protein loss is extreme, human albumin solution may be given through a vein. The purpose is to increase the blood albumin level quickly, pulling fluid back into the bloodstream and reducing edema, ascites, and low blood pressure. The mechanism is oncotic: albumin acts like a sponge for water inside blood vessels. Dosing depends on body weight and severity of low albumin. Risks include fluid overload, allergic reactions, and high cost, so albumin is usually combined with nutrition and treatment of active disease. -
Red-blood-cell (RBC) transfusion for life-threatening anemia
Packed RBC transfusions are used when hemoglobin is dangerously low or there is active bleeding. The purpose is immediate correction of oxygen-carrying capacity to protect the heart, brain, and other organs. Mechanistically, donor red cells directly increase hemoglobin and hematocrit. Transfusions are carefully matched to blood type and given in hospital. Risks include transfusion reactions, iron overload with repeated transfusions, and infection risk, so they are reserved for clear indications and followed by iron and disease-control strategies. -
Proton-pump inhibitors (PPIs) for upper-GI protection
Drugs like omeprazole or pantoprazole reduce stomach acid. While CEAS mainly affects the small intestine, acid suppression may protect the upper digestive tract and reduce bleeding from associated lesions. The purpose is to lower acid-related injury and help existing ulcers heal. Mechanistically, PPIs block the proton pump in stomach parietal cells, reducing acid secretion and raising gastric pH. Typical dosing is once daily before breakfast, adjusted by the physician. Side effects can include headache, diarrhea, and, with long-term use, possible nutrient malabsorption. -
Azathioprine (IMURAN) in selected off-label cases
Most reports suggest immunosuppressants often do not work well in CEAS, but there are rare case reports of benefit with azathioprine in adolescents. The purpose is to reduce immune-mediated inflammation that may be contributing to ulcer formation in specific patients. Mechanistically, azathioprine is a purine antimetabolite that inhibits lymphocyte proliferation and dampens immune responses. Dosing is weight-based and requires careful blood-test monitoring for bone-marrow suppression and liver toxicity, according to the FDA label. Side effects include low white blood cells, infection risk, nausea, liver enzyme elevation, and increased risk of lymphoma with long-term use. Because evidence is limited, azathioprine should only be considered in specialized centers. -
Biologic anti-TNF agents (infliximab and biosimilars – limited benefit overall)
Anti-TNF medicines like infliximab are standard drugs for Crohn’s disease, but studies and case series show that they often fail to give lasting benefit in CEAS. The purpose of trying them, when used, is to see whether blocking TNF-α might reduce inflammation and avoid surgery in selected patients. Mechanistically, infliximab is a monoclonal antibody that binds TNF-α, lowering inflammatory signaling. It is given as IV infusions at weeks 0, 2, and 6, then every 8 weeks, with dosing based on weight according to the FDA label. Side effects include serious infections, infusion reactions, and increased risk of certain cancers, so careful screening and monitoring are essential. Given the low response rate in CEAS, many experts avoid prolonged anti-TNF therapy unless there are overlapping Crohn-like features. -
Gut-selective integrin blocker (vedolizumab – experimental in CEAS)
Vedolizumab is an antibody that blocks α4β7 integrin, preventing inflammatory cells from homing to the gut. It is effective in ulcerative colitis and Crohn’s disease, but there are no strong data in CEAS. The purpose, when used off label, is to limit gut-specific inflammation with a potentially safer systemic profile than some other biologics. Mechanistically, vedolizumab reduces lymphocyte traffic into intestinal tissue, which can lower local inflammation. Dosing (IV or subcutaneous) follows the FDA label used for inflammatory bowel disease. Side effects include infusion reactions, infections, headache, and joint pain. Because evidence in CEAS is minimal, treatment should ideally be within research or after multidisciplinary discussion. -
Broad-spectrum antibiotics during acute complications
When there is concern for bacterial overgrowth, perforation, or post-operative infection, doctors may use antibiotics such as third-generation cephalosporins plus metronidazole. The purpose is to treat or prevent serious infections that can occur in severely malnourished patients with intestinal ulcers and central lines. Mechanistically, these drugs reduce bacterial load and prevent spread of infection to the bloodstream or peritoneum. Dosing and duration are fully individualized based on cultures and infection severity. Side effects vary by drug but can include allergic reactions, diarrhea, and antibiotic-associated colitis. -
Pain-control medicines that avoid NSAIDs
For pain management, doctors prefer options such as paracetamol (acetaminophen) and, when necessary, carefully supervised weak opioids, rather than NSAIDs. The purpose is to control pain without worsening mucosal injury. Mechanistically, paracetamol acts mainly in the central nervous system, while opioids act on pain receptors in the brain and spinal cord. Dosing is strictly controlled to avoid liver toxicity (with paracetamol) and dependence or constipation (with opioids). These medicines should only be used under medical supervision, especially in young patients.
Dietary molecular supplements
Evidence for specific supplements in CEAS is limited, so any supplement should be discussed with the treating team. Below are examples of supplements commonly considered in chronic intestinal disease; they support general health rather than directly treating the genetic defect.
-
Oral elemental iron – strengthens red-blood-cell production by providing iron for hemoglobin.
-
Vitamin B12 – supports red-blood-cell formation and nerve health, especially when the terminal ileum is affected.
-
Folate (vitamin B9) – works with B12 in DNA synthesis for developing blood cells.
-
Vitamin D – supports bone health and immune function, often low in chronic gut disease.
-
Calcium – protects bones, especially if steroids were ever used.
-
Zinc – helps immune function and wound healing in inflamed mucosa.
-
Magnesium – can be depleted with chronic diarrhea and TPN.
-
Omega-3 fatty acids – may have mild anti-inflammatory effects and support cardiovascular health.
-
Probiotics – may help maintain a healthier gut microbiome, though data in CEAS are very limited.
-
Multivitamin and trace-element preparations – cover multiple mild deficiencies in undernourished patients.
For each, the purpose is to correct measured deficiencies and support normal cell function. Mechanistically, these molecules serve as cofactors, structural components, or signaling molecules in blood, bone, and immune pathways. Doses are chosen based on blood-test results, age, and kidney function, and excessive self-supplementation can be harmful.
Immunity-booster, regenerative, and stem-cell–related drugs
At present, there are no approved “stem cell drugs” or specific immunity boosters for CEAS. Some concepts below are used in other diseases and may be discussed theoretically in research settings, but they are not standard treatment for this condition.
-
Erythropoiesis-stimulating agents (ESAs)
These are synthetic forms of erythropoietin used in selected anemias to stimulate bone marrow red-cell production. In theory, they could help persistent anemia once iron is corrected, but they are usually reserved for kidney disease or chemotherapy-related anemia. They work by binding EPO receptors on marrow cells, pushing them to produce more red cells. They carry risks of high blood pressure and clotting and are not routine for CEAS. -
Growth-factor support for white cells (G-CSF)
Granulocyte colony-stimulating factor boosts white-blood-cell production in the bone marrow. In CEAS, it might be considered only if severe neutropenia occurs due to other medications, not as a direct treatment of the enteropathy. Its purpose would be to reduce infection risk. Mechanistically, it signals progenitor cells to mature into neutrophils. Side effects include bone pain and very rarely splenic complications. -
Experimental mesenchymal stem-cell infusions (research only)
In some forms of refractory inflammatory bowel disease, experimental trials have used mesenchymal stem cells to promote mucosal healing and immune regulation. For CEAS, there is no established evidence yet. Theoretically, these cells might home to inflamed tissue, release anti-inflammatory factors, and support tissue repair. However, risks, long-term safety, and effectiveness are unknown, so such treatments should only be considered within formal clinical trials, if at all.
Because these approaches are specialized and high-risk, patients and families should discuss them only with expert centers; they are not self-care options.
Surgeries (procedures and why they are done)
Surgery is unfortunately common in CEAS, especially when strictures, repeated bleeding, or perforation develop. The goal is to remove or bypass the worst-affected segments while keeping as much healthy bowel as possible.
-
Segmental small-bowel resection
In this operation, surgeons remove segments of small intestine with severe ulcers, strictures, or bleeding and then join the healthy ends together (anastomosis). The purpose is to stop ongoing blood and protein loss, relieve obstruction, and remove tissue at risk of perforation. Mechanistically, taking out the worst-damaged bowel reduces inflammatory load and can temporarily improve anemia and nutrition. However, repeated resections can lead to short-bowel syndrome and malabsorption. -
Stricturoplasty
Stricturoplasty widens narrowed segments of intestine without removing them. The surgeon cuts along the stricture and then closes it in a way that increases diameter. The purpose is to relieve obstruction while preserving bowel length. The mechanism is purely mechanical: widening the lumen allows food and stool to pass more easily. This technique may be considered when there are multiple short strictures or when bowel length is already reduced. -
Creation of a temporary stoma (ileostomy or jejunostomy)
Sometimes, a part of the small intestine is brought out through the abdominal wall to form a stoma, and stool empties into a bag. The purpose is to divert flow away from severely diseased or newly operated segments so they can heal. Mechanistically, diversion decreases pressure, bacteria, and bile acid exposure to the affected segments. Once the bowel is stable, the stoma may be reversed, but in some cases it becomes long-term. -
Endoscopic balloon dilation of strictures
For short, accessible strictures, endoscopists may use balloon catheters to dilate the narrowed area during an enteroscopy procedure. The purpose is to delay or avoid surgery by improving passage through the stricture. Mechanistically, controlled stretching of scar tissue enlarges the lumen. Risks include perforation and bleeding, so this is done in experienced centers. -
Placement of central venous catheters for long-term TPN
When TPN is needed for months, a tunneled central line or implanted port is surgically placed. The purpose is to provide safe, long-term venous access for nutrition, medicines, and blood draws. Mechanistically, it offers a large, stable vein with lower risk of repeated needle damage. Risks include line infection and clotting, so strict care protocols are essential.
Prevention and lifestyle strategies
Because CEAS is genetic, it cannot be fully prevented, but complications can often be reduced. Helpful strategies include:
-
Early recognition and referral for unexplained iron deficiency anemia and small-bowel ulcers.
-
Genetic testing for SLCO2A1 when CEAS is suspected, to avoid years of misdiagnosis as Crohn’s disease.
-
Avoidance of NSAIDs and other mucosal-damaging drugs whenever possible.
-
Regular monitoring of blood counts, albumin, and weight/growth.
-
Prompt treatment of anemia with appropriate iron therapy.
-
Adequate calorie and protein intake with specialist dietetic support.
-
Smoking avoidance (for older patients), because smoking worsens many bowel diseases.
-
Keeping vaccinations up to date, especially when immunosuppressive drugs are used.
-
Early consultation with surgeons before obstruction or perforation becomes an emergency.
-
Ongoing psychological and social support to improve adherence and overall well-being.
When to see a doctor
Anyone with suspected or confirmed CEAS should contact a doctor or go to hospital urgently if they have:
-
Persistent or worsening abdominal pain, vomiting, or a swollen abdomen, which may signal obstruction or perforation.
-
Black, tarry, or bloody stools, or vomiting blood, which suggests active bleeding.
-
Severe tiredness, dizziness, paleness, or shortness of breath, which may reflect severe anemia.
-
Rapid weight loss, poor growth, or loss of appetite, especially in children or teenagers.
-
Fever, chills, or signs of infection, particularly if they have a central line or are on immunosuppressive drugs.
Regular planned follow-up visits are also essential, even when symptoms seem quiet, because CEAS can silently cause anemia and low albumin.
Diet: what to eat and what to avoid
There is no single “CEAS diet,” but many doctors recommend a gentle, bowel-friendly eating pattern tailored to the patient’s nutritional status and symptoms.
Helpful to eat (under dietitian guidance):
-
Soft, low-fiber carbohydrates such as white rice, refined pasta, and soft bread to provide energy without much roughage.
-
Easily digested protein like eggs, fish, skinless poultry, tofu, yogurt, and smooth nut butters to rebuild albumin and muscle.
-
Cooked fruits and vegetables without skins or seeds, for example peeled carrots, pumpkin, and applesauce, to supply vitamins with less fiber.
-
Oral nutrition supplements or shakes, chosen for appropriate calories, protein, and micronutrients.
-
Plenty of safe fluids (water, oral rehydration solutions, weak tea) to replace losses from diarrhea and maintain circulation.
Often wise to limit or avoid (individualized):
-
Very high-fiber, coarse foods like raw cabbage, popcorn, nuts with skins, and seeds, which can irritate strictures.
-
Fatty, fried, or heavily spiced meals, which may worsen diarrhea and pain.
-
Alcohol and smoking in adults, as they can worsen mucosal damage and interfere with healing.
-
Sugary soft drinks and energy drinks, which add empty calories and can aggravate diarrhea.
-
Over-the-counter NSAID painkillers, unless specifically approved by the treating team.
All dietary changes should be supervised by a clinician and dietitian, especially in children, to avoid malnutrition.
Frequently asked questions (FAQs)
1. Is CEAS the same as Crohn’s disease?
No. CEAS and Crohn’s disease can look similar on scans and endoscopy because both cause small-bowel ulcers and strictures. However, CEAS is a monogenic disorder caused by SLCO2A1 mutations, and inflammatory markers like CRP can be normal. Many standard Crohn’s drugs work poorly in CEAS, and genetic testing is needed to confirm the diagnosis.
2. How is CEAS diagnosed?
Doctors combine clinical history (chronic anemia, protein loss), endoscopic imaging (multiple small-bowel ulcers), and advanced imaging such as CT or MR enterography. Capsule endoscopy can reveal ulcers not seen on standard scopes. Genetic testing then looks for disease-causing SLCO2A1 mutations to secure the diagnosis.
3. Why does the SLCO2A1 mutation cause gut ulcers?
SLCO2A1 encodes a prostaglandin transporter that moves PGE2 into cells for breakdown. In CEAS, loss-of-function mutations reduce PGE2 uptake, leading to higher local PGE2 levels and altered inflammatory signaling. This imbalance disrupts mucosal integrity in the small intestine, promoting chronic shallow ulcers and bleeding.
4. Is there a cure for CEAS yet?
Currently there is no cure that corrects the gene defect or fully reverses the disease. Treatment focuses on correcting anemia and low albumin, maintaining nutrition, and managing strictures and bleeding. Research on SLCO2A1 biology and prostaglandin pathways is ongoing and may lead to targeted therapies in the future.
5. Do biologic drugs always fail in CEAS?
Not always, but many reports show limited or no response to anti-TNF agents and other biologics that work well in Crohn’s disease. A few individual patients may benefit, but overall effectiveness is low, and surgery is still frequently required. Decisions about biologics must be individualized and made in expert centers.
6. Why is anemia so common in CEAS?
Anemia develops because chronic small-bowel ulcers slowly leak blood, and poor absorption and reduced appetite make it hard to replace iron and other nutrients. Over time, iron stores become very low, leading to iron deficiency anemia. This is why IV iron and, when necessary, transfusions are central parts of treatment.
7. Can children with CEAS grow normally?
Growth delay is common in pediatric CEAS due to chronic malnutrition, anemia, and protein loss. With early diagnosis, intensive nutritional support, and careful management of anemia and complications, many children can improve growth, but close monitoring by pediatric gastroenterologists is essential.
8. Is surgery always necessary?
Not every patient needs surgery, but many eventually require it due to strictures, bleeding, or perforation. The goal is to operate only when clearly needed and to preserve as much bowel as possible. Good medical and nutritional management can sometimes delay surgery or reduce the number of procedures needed.
9. Can CEAS affect organs outside the gut?
Because SLCO2A1 also plays a role in other tissues, some patients with SLCO2A1 mutations develop primary hypertrophic osteoarthropathy, with clubbing of the fingers, thickening of the skin, and bone changes. Not all CEAS patients have these features, but the overlap shows how prostaglandin transport affects multiple systems.
10. Is CEAS common in any particular region?
Most reported cases so far come from East Asian countries such as Japan, South Korea, and China, though cases have now been described in Europe, South Asia, and other regions. This pattern may partly reflect where genetic testing is widely available and where the disease was first recognized.
11. Can lifestyle changes alone control CEAS?
Lifestyle measures such as a gentle diet, avoiding NSAIDs, not smoking, and keeping vaccinations current are very important, but they cannot replace medical treatments. Because the underlying problem is genetic, medical and sometimes surgical care remain essential to prevent serious complications.
12. Is pregnancy possible in people with CEAS?
Pregnancy may be possible, but it requires careful planning with gastroenterologists, high-risk obstetricians, and genetic counselors. Nutritional status, anemia, and medication safety must be reviewed before conception and throughout pregnancy. Because CEAS is autosomal recessive, the chance of affected children depends on the partner’s carrier status.
13. How often should follow-up tests be done?
There is no single schedule, but many experts recommend regular checks of blood counts, albumin, iron studies, and weight or growth, with imaging (capsule endoscopy, CT/MR enterography) when symptoms change or anemia worsens unexpectedly. Follow-up frequency is higher during unstable periods and after surgery.
14. Can family members be tested?
Yes. Once a disease-causing SLCO2A1 variant is found in one patient, first-degree relatives can be offered genetic counseling and testing. This helps identify carriers and any other affected siblings, allowing early monitoring and treatment before complications become severe.
15. What should patients avoid doing on their own?
Patients should not start, stop, or change doses of prescription medicines, iron injections, or supplements without medical advice; should not self-diagnose based on internet information; and should not ignore warning signs such as severe pain, bleeding, or rapid weight loss. Because CEAS is rare and complex, decisions must be made together with experienced doctors.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: January 23, 2026.
